Drug Insights

Master Doxycycline Search on Synapse

31 January 2024
2 min read

Doxycycline is a tetracyclin-like broad-spectrum antibiotic that stops bacteria from growing and replicating by inhibiting the synthesis of bacterial proteins. Doxycycline mechanisms by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome A site. This hinders the production of proteins and ultimately leads to the death of bacterial cells. Doxycycline is widely used to treat respiratory infections, urinary tract infections and sexually transmitted infections caused by bacteria. Its effectiveness, versatility and low cost make it a valuable tool in the fight against infectious diseases. Click on the image below to begin the exploration journey of Doxycycline through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Unveiling Omeprazole: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Omeprazole: How to Search for it on Synapse
31 January 2024
Omeprazole, a common PPI, is used to treat gastrointestinal conditions like GERD, peptic ulcers, and Zollinger-Ellison syndrome.
Read →
8-Year Study Reveals Superior Survival with Opdivo-Yervoy vs Sunitinib for Untreated Advanced Kidney Cancer
Latest Hotspot
3 min read
8-Year Study Reveals Superior Survival with Opdivo-Yervoy vs Sunitinib for Untreated Advanced Kidney Cancer
31 January 2024
Long-term results show Opdivo combined with Yervoy outlasts Sunitinib in survival outcomes for advanced or metastatic kidney cancer patients who haven't received prior treatment over an 8-year period.
Read →
Expert Tips for Searching Lisinopril on Synapse
Drug Insights
2 min read
Expert Tips for Searching Lisinopril on Synapse
31 January 2024
Lisinopril is an ACE inhibitor often prescribed for hypertension, heart failure, and other heart conditions.
Read →
FDA Approves Vanda Pharmaceuticals' VCA-894A Therapy for Charcot-Marie-Tooth Disease 2S
Latest Hotspot
3 min read
FDA Approves Vanda Pharmaceuticals' VCA-894A Therapy for Charcot-Marie-Tooth Disease 2S
31 January 2024
Vanda Pharmaceuticals Granted Green Light by FDA to Advance with Experimental Antisense Oligonucleotide Therapy, VCA-894A, for Managing Charcot-Marie-Tooth Disease, Subtype 2S.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.